ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 601

Development of an Optimized Online Self-Referral Tool for Early Recognition of Patients with Axial Spondyloarthritis – Data from the OptiRef Study

Fabian Proft1, Laura Spiller 2, Mikhail Protopopov 3, Valeria Rios Rodriguez 2, Burkhard Muche 2, Judith Rademacher 2, Susanne Lüders 2, Anne Katrin Weber 2, Imke Redeker 4 and Denis Poddubnyy 5, 1Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, 2Charité Universitätsmedizin, Berlin, Germany, 3Charité Universitätsmedizin Berlin, Germany, Berlin, Berlin, Germany, 4Charité – Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, 5Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: axial spondyloarthritis, Referrals and digital technologies

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: One of the major reasons for a long diagnostic delay in axial spondyloarthritis (axSpA) is the late referral of patients by primary care physicians dealing with patients with chronic back pain. We developed and implemented an online self-referral tool (www.bechterew-check.de), which gave access to a rheumatological consultation if patients declared suffering from chronic back pain (≥ 3 months) with a symptom onset ≤ 45 years of age, and at least one feature indicative of SpA. In the prospective “Identification of the Optimal Referral Strategy for Early Diagnosis of Axial Spondyloarthritis (OptiRef) Study” we could diagnose axSpA in 19% of the self-referred patients. The objective was to optimize the online-self-referral tool for recognition of patients with high suspicion of axSpA in order to increase the specificity by keeping the high level of sensitivity.

Methods: 181 patients who had fulfilled the online self-referral strategy were included and underwent a standardized rheumatology examination. The final diagnosis of axial SpA / no axial SpA by the rheumatologist served as the gold standard. The performance of all possible combinations of the referral parameters (13 parameters in total including 5 features of inflammatory back pain (IBP) and 8 other SpA features) added to both stem parameters (chronic back pain starting at age of ≤45 years) was tested. In addition, the following pre-specified combinations were evaluated: 1) ≥1 IBP parameter AND ≥1 other SpA parameter, 2) ≥1 IBP parameter OR ≥1 other SpA parameter. For all combinations, a sensitivity, a specificity, positive and negative predictive values (PPV and NPV), as well as a positive and negative likelihood ratio (LR+ and LR-) were calculated. We targeted the maximal specificity by acceptable sensitivity (defined as ≥90% of the original strategy).

Results: For 163 of the included patients, full data of the online questionnaire as well as of rheumatology examination including the final diagnosis was available. 31 (19%) of them were diagnosed with axial SpA. Raising the threshold of the number of positive parameters (table 1) resulted in a quick drop of the sensitivity. According to the pre-defined selection criterion, only a strategy with any four positive parameters would be acceptable. An analysis of combined strategies (IBP parameters and/or other SpA parameters) resulted into identification of a strategy with an improved performance: a combination of ≥2 IBP parameters with ≥1 other SpA parameters (in addition to both stem parameters) showed a sensitivity of 90% (28/31), a specificity of 27% (35/132), a PPV of 22% (28/125), a NPV of 92% (35/38), LR+ of 1.23 and LR- of 0.36. Thus, identifying 28 of 31 patients with axSpA would have been possible after the assessment of 125 patients instead of 163.

Conclusion: The data-driven optimized online self-referral tool (figure 1) requires the following parameters to be positive: chronic back pain (≥3 months) plus back pain onset before 45 years of age plus ≥2 IBP parameters plus ≥1 other SpA feature. The performance of this tool should be confirmed in a prospective study.


Figure 1


Table 1


Disclosure: F. Proft, Abbvie, 5, 8, BMS, 8, MSD, 8, Novartis, 5, 8, Novartis Pharma, 2, Pfizer, 5, 8, Roche, 8, UCB, 5, 8; L. Spiller, None; M. Protopopov, MSD, 8, Novartis, 5, 8, Pfizer, 8; V. Rios Rodriguez, AbbVie, 5, 8, MSD, 5, 8, Novartis, 5, 8; B. Muche, None; J. Rademacher, None; S. Lüders, None; A. Weber, None; I. Redeker, None; D. Poddubnyy, Abbvie, 2, 5, 8, AbbVie, 2, 5, 8, BMS, 5, 8, Celgene, 5, 8, Eli Lilly, 5, 8, Eli Lilly and Company, 2, 5, 8, Lilly, 5, 8, MSD, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Roche, 5, 8, UCB, 5, 8.

To cite this abstract in AMA style:

Proft F, Spiller L, Protopopov M, Rios Rodriguez V, Muche B, Rademacher J, Lüders S, Weber A, Redeker I, Poddubnyy D. Development of an Optimized Online Self-Referral Tool for Early Recognition of Patients with Axial Spondyloarthritis – Data from the OptiRef Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/development-of-an-optimized-online-self-referral-tool-for-early-recognition-of-patients-with-axial-spondyloarthritis-data-from-the-optiref-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-an-optimized-online-self-referral-tool-for-early-recognition-of-patients-with-axial-spondyloarthritis-data-from-the-optiref-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology